Previous close | 0.8500 |
Open | 0.9000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 1.00 |
Expiry date | 2025-01-17 |
Day's range | 0.8500 - 0.9000 |
Contract range | N/A |
Volume | |
Open interest | 7.75k |
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Ocugen’s leadership team will host meetings with potential partners and pharmaceutical executives to explore oppo
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. “Inclusion of O
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.